(Q39756798)

14 September 2017

Overall survival and PD-L1 expression in metastasized malignant melanoma (English)

1 reference

14 September 2017

6

Christian Blank

1 reference

14 September 2017

Jules Gadiot

1

1 reference

14 September 2017

Anna I Hooijkaas

2

1 reference

14 September 2017

Andrew D M Kaiser

3

1 reference

14 September 2017

Harm van Tinteren

4

1 reference

14 September 2017

Hester van Boven

5

1 reference

14 September 2017

language of work or name

English

0 references

publication date

29 November 2010

1 reference

14 September 2017

1 reference

14 September 2017

117

1 reference

14 September 2017

2192-2201

1 reference

14 September 2017

10

1 reference

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

14 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Therapeutic vaccines in solid tumours: can they be harmful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Immunotherapy: Vaccine trials in melanoma -- time for reflection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Immune modulation by melanoma-derived factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

B7 family molecules: novel immunomodulators at the maternal-fetal interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

B7 family molecules are favorably positioned at the human maternal-fetal interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Model predicting survival in stage I melanoma based on tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

7 January 2021

Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

7 January 2021

PD-1: an inhibitory immunoreceptor involved in peripheral tolerance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

7 January 2021

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

7 January 2021

Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

7 January 2021

Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25747

7 January 2021

Identifiers

DOI

10.1002/CNCR.25747

1 reference

14 September 2017

1 reference